Literature DB >> 17296469

A "new age" in pertussis prevention new opportunities through adult vaccination.

Margaret M Cortese1, Andrew L Baughman, Kristin Brown, Pamela Srivastava.   

Abstract

BACKGROUND: For the first time, pertussis vaccines for adolescents and adults (combined with tetanus and diphtheria toxoids [Tdap]) became available in the United States in 2005. Despite a fully implemented U.S. childhood pertussis vaccination program, substantial morbidity because of pertussis continues to occur. To reduce this morbidity, the Advisory Committee on Immunization Practices recommended Tdap for all adolescents and adults in place of the next tetanus-diphtheria booster. As background for the basis of these recommendations, we summarize data on the morbidity and incidence of pertussis in U.S. adults and the role of adults in transmitting pertussis to young infants.
METHODS: A MEDLINE search was performed in March 2006 for data on pertussis incidence rates and cough illness because of pertussis among U.S. adults (prospective, nonoutbreak studies were selected) and pertussis complications in adults. Data from the national passive surveillance system were also analyzed in October 2005.
RESULTS: The true adult burden is estimated at more than 600,000 cases annually in the United States. Adults with pertussis commonly cough for 2-4 months, often resulting in repeated medical visits and missed work. Complications include pneumonia, rib fractures, and cough syncope. Adults are an important source of pertussis for young infants, who have the highest risk of hospitalization and death.
CONCLUSIONS: The morbidity from pertussis in adults can be substantial, the incidence of pertussis in U.S. adults is high, and adults transmit infection to young infants. Providers now have the opportunity to reduce the burden of pertussis by vaccinating adults with Tdap.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296469     DOI: 10.1016/j.amepre.2006.10.015

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  12 in total

1.  Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention.

Authors:  Michael D Parkins; Shelly A McNeil; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

2.  Advances in vaccine technology and their impact on managed care.

Authors:  Jonathan A McCullers; Jeffrey D Dunn
Journal:  P T       Date:  2008-01

3.  Assessing the impact of a pertussis active surveillance program on provider testing behavior, Minnesota 2005-2009.

Authors:  Cynthia Kenyon; Emily Banerjee; Kristin Sweet; Claudia Miller; Kristen Ehresmann
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

4.  Potential impact of parental Tdap immunization on infant pertussis hospitalizations.

Authors:  Timothy R Peters; Gretchen C Banks; Beverly M Snively; Katherine A Poehling
Journal:  Vaccine       Date:  2012-06-27       Impact factor: 3.641

5.  Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries.

Authors:  Mirjam Kretzschmar; Peter F M Teunis; Richard G Pebody
Journal:  PLoS Med       Date:  2010-06-22       Impact factor: 11.069

6.  Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice.

Authors:  Charlotte Andreasen; Nicholas H Carbonetti
Journal:  Infect Immun       Date:  2008-09-02       Impact factor: 3.441

7.  Is Pertussis Infection Neglected in China? Evidence from a Seroepidemiology Survey in Zhejiang, an Eastern Province of China.

Authors:  Hanqing He; Pingping Yao; Yang Zhou; Xuan Deng; Jinren Pan
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

8.  Asymptomatic transmission and the resurgence of Bordetella pertussis.

Authors:  Benjamin M Althouse; Samuel V Scarpino
Journal:  BMC Med       Date:  2015-06-24       Impact factor: 8.775

9.  Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly.

Authors:  Lisa J McGarry; Girishanthy Krishnarajah; Gregory Hill; Michelle Skornicki; Narin Pruttivarasin; Cristina Masseria; Bhakti Arondekar; Stephen I Pelton; Milton C Weinstein
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

10.  Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission.

Authors:  Lisa J McGarry; Girishanthy Krishnarajah; Gregory Hill; Cristina Masseria; Michelle Skornicki; Narin Pruttivarasin; Bhakti Arondekar; Julie Roiz; Stephen I Pelton; Milton C Weinstein
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.